Expert Interview
Exploring Travere Therapeutics Inc.'s phase 3 trial of sparsentan and irbesartan for patients with focal segmental glomerulosclerosis
Ticker(s): TVTXInstitution: University of Iowa
- Clinical Professor of Internal Medicine - Nephrology, and Medical Director for dialysis at University of Iowa
- Currently manages 30+ patients with focal segmental glomerulosclerosis and 200 patients for potassium management
- Research interests in IgA neuropathy, renal transplantation outcomes, and kidney dialysis
What are your thoughts on the phase 3 trial data for sparsentan and irbesartan?
Added By: emily_adminWhat impact do you think sparsentan and irbesartan will have on the treatment space for patients with focal segmental glomerulosclerosis?
Added By: emily_adminWhat are your thoughts on the mechanism of action of sparsentan and irbesartan?
Added By: emily_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
